Major Depression Clinical Trial
Official title:
A Placebo Controlled Clinical Trial of a Standardized Extract of Hypericum Perforatum in Major Depressive Disorder
The purpose of this trial is to study the acute efficacy and safety of a standardized
extract of the herb Hypericum perforatum (St. John's Wort), called hypericum for purposes of
this trial, in the treatment of patients with major depression.
Clinical depression is a serious medical disorder that can be debilitating and can lead to
suicide. There is growing public interest in claims that hypericum may be an effective
treatment for depression. Although it is widely prescribed in Europe, no studies of its
long-term use have been conducted, and published studies have treated different types of
patients and have used several different doses. The toxicity and side effects of hypericum
appear to be substantially less than those of standard tricyclic antidepressant medications,
and thus hypericum may be more acceptable to patients. In addition, the cost is
significantly less than standard antidepressant medications. Published studies assessed
acute efficacy and lasted between 4 and 12 weeks (most being 4-6 weeks). The longer-term
effects of hypericum have not been evaluated. There is a need for a large-scale, controlled
clinical trial to assess whether Hypericum has a significant therapeutic effect in patients
with clinical depression.
Patients are assigned randomly (like tossing a coin) to receive St. John's wort, Sertraline
(Zoloft), or a placebo (sugar pill) for 8 weeks. This is a double-blind study, meaning
neither the patient nor the doctor will know which treatment is being assigned. Patients who
respond well to the treatment will continue on the assigned treatment for an additional 4
months. Patients will have regular follow-up visits to monitor their symptoms and any side
effects they experience.
This trial will determine the acute antidepressant efficacy of a standardized extract of
hypericum (St. John's Wort) for the treatment of major depressive disorder.
For this trial, the primary efficacy analysis will be evaluated at 8 weeks. For
observational purposes, a 4-month double blind continuation (6 months total treatment) in
treatment responders would enable an approximation of the effectiveness of maintenance
treatment with this medication. No published studies have included a selective serotonin
re-uptake inhibitor (SSRI) comparator. While this trial will not compare the efficacy of
hypericum to an SSRI, having an SSRI arm of sertraline (Zoloft) will allow an evaluation of
the validity of the trial.
336 eligible patients will be randomly assigned to double-blind treatment with hypericum,
sertraline, or placebo following a one-week placebo lead-in period (between screening and
baseline). All treatment groups will consist of 112 patients and will be followed for an
eight-week period. Treatment responders will be continued on the randomly assigned treatment
arm for an additional 18 weeks.
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00149110 -
Chronos: the Use of Chronobiological Treatment in Depression
|
N/A |